Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 7, 2008

PPD Plans to Acquire InnoPharm to Augment Its Eastern European Presence

  • PPD has agreed to purchase InnoPharm to expand its CRO services into Russia and Ukraine. “With more than 143 million people in Russia alone, Eastern Europe is a high-growth market for clinical trials and a region PPD has targeted for expansion,” comments Fred Eshelman, CEO of PPD.

    Innopharm is headquartered in Smolensk, Russia, and has offices in Moscow and St. Petersburg as well as Kiev, Ukraine. The firm offers Phase II-IV trials support, data management, and biostatistics services.

    “We have subcontracted work to InnoPharm since 2004 and have great confidence in the team's clinical research capabilities and its commitment to quality,” Eshelman adds. “In addition to extending our geographic footprint and enhancing our ability to conduct global studies for our clients, we are gaining a high-caliber group of clinical research professionals.”

    The acquisition is expected to close in the second quarter.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »